Mission Statement
The ISHAM ABPA Working Group is dedicated to advancing the understanding, diagnosis, and treatment of ABPA. Through collaborative research, education, and advocacy, we strive to improve patient outcomes, promote innovative therapies, and increase awareness among healthcare professionals and the public. Our mission is to foster a global network of experts committed to excellence in ABPA care, ensuring a better quality of life for those affected by this condition.
Achievements of the working group in 2023
The ABPA working group made significant strides in diagnosing and managing ABPA with the publication of revised guidelines in the European Respiratory Journal. Using a modified Delphi method, we conducted online surveys between 15th June and 15th August 2023. We sent out invitations to 43 experts, of whom 39 participated (13 countries across six continents). The revised ISHAM-ABPA guidelines represent a comprehensive update, incorporating the latest research and clinical practices. One of the key achievements is the refinement of diagnostic criteria, enhancing the accuracy of ABPA diagnosis. The guidelines provide a more precise delineation between ABPA and other Aspergillus-related conditions, reducing the risk of misdiagnosis and ensuring that patients receive appropriate and timely treatment. Furthermore, the guidelines introduced updated recommendations for managing ABPA, emphasizing a multidisciplinary approach. This includes a combination of antifungal therapy, corticosteroids, and immunomodulatory treatments tailored to the severity and stage of the disease. This consensus guideline for diagnosing, classifying, and treating ABPA and ABPM will bring uniformity and simplify the inclusion of patients in clinical trials.
Upcoming events planned for 2024-2025
In 2024-2025, the ABPA working group plans to disseminate the revised ISHAM-ABPA working group guidelines.
Publications arising from the Working Group
- Agarwal R, Muthu V, Sehgal IS. Relationship between Aspergillus and asthma. Allergol Int 2023; 72(4): 507-520.
- Agarwal R, Muthu V, Sehgal IS. Clinical Manifestation and Treatment of Allergic Bronchopulmonary Aspergillosis. Semin Respir Crit Care Med 2023; 45(01): 114-127.
- Agarwal R, Muthu V, Sehgal IS, Dhooria S, Prasad KT, Soundappan K, Rudramurthy SM, Aggarwal AN, Chakrabarti A. Aspergillus Sensitization and Allergic Bronchopulmonary Aspergillosis in Asthmatic Children: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2023; 13(5): 922.
- Agarwal R, Muthu V, Sehgal IS, Dhooria S, Prasad KT, Soundappan K, Rudramurthy SM, Aggarwal AN, Chakrabarti A. Prevalence of Aspergillus sensitization and Allergic Bronchopulmonary Aspergillosis in bronchial asthma: A systematic review of Indian studies. Lung India 2023; 40(6): 527-536.
- Agarwal R, Muthu V, Sehgal IS, Dhooria S, Prasad KT, Soundappan K, Rudramurthy SM, Aggarwal AN, Chakrabarti A. Prevalence of Aspergillus Sensitization and Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma: A Systematic Review of Global Data. J Allergy Clin Immunol Pract 2023; 11(6): 1734-1751 e3.
- Agarwal R, Sehgal IS, Muthu V, Dhar R, Armstrong-James D. Allergic bronchopulmonary aspergillosis in India. Clin Exp Allergy 2023; 53(7): 751-764.
- Agarwal R, Sehgal IS, Muthu V, Dhooria S, Prasad KT, Aggarwal AN, Garg M, Rudramurthy SM, Chakrabarti A. Long-term follow-up of allergic bronchopulmonary aspergillosis treated with glucocorticoids: A study of 182 subjects. Mycoses 2023; 66(11): 953-959.
- Jin M, Douglass JA, Elborn JS, Agarwal R, Calhoun WJ, Lazarewicz S, Jaumont X, Yan M. Omalizumab in allergic bronchopulmonary aspergillosis (ABPA): A systematic review and meta-analysis. J Allergy Clin Immunol Pract 2023.
- Madhavan V, Muthu V, Sehgal IS, Dhooria S, Prasad KT, Aggarwal AN, Agarwal R. Malnutrition in allergic bronchopulmonary aspergillosis complicating asthma. Lung India 2023; 40(6): 563-566.
- Muthu V, Dhooria S, Sehgal IS, Prasad KT, Rudramurthy SM, Aggarwal AN, Chakrabarti A, Agarwal R. Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis. Pulm Pharmacol Ther 2023; 81: 102226.
- Ram B, Muthu V, Prasad KT, Sehgal IS, Dhooria S, Aggarwal AN, Agarwal R. Bronchodilator responsiveness is less common in allergic bronchopulmonary aspergillosis-complicating asthma than asthma alone. J Allergy Clin Immunol Pract 2023; 11(12): 3780-82.
- Sehgal IS, Dhooria S, Muthu V, Rudramurthy SM, Prasad KT, Chakrabarti A, Aggarwal AN, Agarwal R. Identification of distinct immunophenotypes in chronic pulmonary aspergillosis using cluster analysis. Mycoses 2023; 66(4): 299-303.
- Sehgal IS, Dhooria S, Soundappan K, Rudramurthy SM, Chakrabarti A, Agarwal R. Comparison of three sample types for performing LDBio Aspergillus immunochromatographic technology lateral flow assay for IgG/IgM antibody detection in chronic aspergillosis. Clin Microbiol Infect 2023; 29(3): 404-405.
- Soundappan K, Muthu V, Dhooria S, Sehgal IS, Prasad KT, Rudramurthy SM, Chakrabarti A, Aggarwal AN, Agarwal R. Population prevalence of allergic bronchopulmonary aspergillosis in asthma: An epidemiological study of 43,261 participants from North India. Clin Exp Allergy 2023; 53(7): 777-780.
Funding provided by ISHAM in the past 3 years
2023: 15.000 CHF + 2310 Euros
